For the validation cohort, we detected 3/1716 (0.17%) RAD50 LOF variants in FH+ ESCC, 4/2148 (0.19%) in sporadic ESCC and 4/2342 (0.17%) in the controls (Table 2). Here, RAD50 is linked to esophageal squamous cell carcinoma.